CRL News and Press, Charles River Laboratories International Inc. From 01/16/24

2024-01-16 09:00:09 ET More on Charles River Laboratories Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation Charles River: Q3 Points To Ongoing Deterioration For further details see: Charles River Laboratories launches Rep/Cap plasmid

Off-the-shelf Rep/Cap simplifies gene therapy supply chains with immediate availability Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus (AAV)-based gene the...

2024-01-15 17:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-01-07 10:35:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The market’s mi...

2023-12-29 17:15:31 ET More on bluebird bio, CRISPR Therapeutics, etc. bluebird bio's Lyfgenia: Navigating Commercialization Challenges In SCD Vertex's Pain Game: VX-548 Takes Aim At Neuropathic Battles Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why M...

Charles River’s Memphis facility approved to manufacture Vertex’s CASGEVY ™ therapy, the world’s first gene-edited therapy targeting severe sickle cell disease Charles River Laboratories International, Inc. (NYSE: CRL) today announced an important mil...

CELLphenomics’ PD3D® tumor model platform will expand Charles River’s portfolio of 3D in vitro testing services Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with CELLphenomics, a service-based biotech...

2023-12-07 13:53:44 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In 2016, there were 49 million Americans aged 65 or older. Analysts forecast that will grow to 73 million retirement-age Americans in 2030 and an eye-opening 95 million in the year 2060. ...

Company will perform plasmid DNA production in support of early phase trials for SPG56 Hereditary Spastic Paraplegia Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc (GC4K), an Australian non-profit foundation focused on research programs and cli...

2023-11-26 09:13:34 ET Summary Charles River Laboratories provides essential products and services to accelerate research and drug development efforts. The company benefits from competitive advantages thanks to the entry barriers, since its clients usually opt for suppliers with g...